These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23243610)

  • 1. NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target.
    Lai JP; Rosenberg AZ; Miettinen MM; Lee CC
    Oncoimmunology; 2012 Nov; 1(8):1409-1410. PubMed ID: 23243610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
    Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
    Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
    Hemminger JA; Iwenofu OH
    Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
    Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y
    Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.
    Kakimoto T; Matsumine A; Kageyama S; Asanuma K; Matsubara T; Nakamura T; Iino T; Ikeda H; Shiku H; Sudo A
    Oncol Lett; 2019 Apr; 17(4):3937-3943. PubMed ID: 30881511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
    Hemminger JA; Ewart Toland A; Scharschmidt TJ; Mayerson JL; Kraybill WG; Guttridge DC; Iwenofu OH
    Mod Pathol; 2013 Feb; 26(2):282-8. PubMed ID: 22936067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
    Endo M; de Graaff MA; Ingram DR; Lim S; Lev DC; Briaire-de Bruijn IH; Somaiah N; Bovée JV; Lazar AJ; Nielsen TO
    Mod Pathol; 2015 Apr; 28(4):587-95. PubMed ID: 25412843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
    Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
    Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
    Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.
    Iura K; Kohashi K; Hotokebuchi Y; Ishii T; Maekawa A; Yamada Y; Yamamoto H; Iwamoto Y; Oda Y
    J Pathol Clin Res; 2015 Jul; 1(3):144-59. PubMed ID: 27499900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7.
    Jungbluth AA; Antonescu CR; Busam KJ; Iversen K; Kolb D; Coplan K; Chen YT; Stockert E; Ladanyi M; Old LJ
    Int J Cancer; 2001 Oct; 94(2):252-6. PubMed ID: 11668506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
    Pollack SM
    Expert Rev Vaccines; 2018 Feb; 17(2):107-114. PubMed ID: 29280411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
    Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
    J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma.
    Jo U; Roh J; Song MJ; Cho KJ; Kim W; Song JS
    Am J Transl Res; 2022; 14(2):1268-1278. PubMed ID: 35273728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
    Park TS; Groh EM; Patel K; Kerkar SP; Lee CC; Rosenberg SA
    J Immunother; 2016 Jan; 39(1):1-7. PubMed ID: 26641256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid liposarcoma].
    Hei SM; Wei HJ; Chen H; Wang JG
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):225-230. PubMed ID: 30831650
    [No Abstract]   [Full Text] [Related]  

  • 17. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis.
    Smith SM; Iwenofu OH
    Chin Clin Oncol; 2018 Aug; 7(4):44. PubMed ID: 30173534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.
    Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Muzikansky A; Kalil J; Festa-Neto C; Duncan LM
    J Immunol Res; 2015; 2015():761378. PubMed ID: 25954764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of XAGE-1b and NY-ESO-1 in metastatic lymph nodes may predict the potential survival of stage III melanoma patients.
    Mori M; Funakoshi T; Kameyama K; Kawakami Y; Sato E; Nakayama E; Amagai M; Tanese K
    J Dermatol; 2017 Jun; 44(6):671-680. PubMed ID: 28105694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.